Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
US Indexes Mostly Lower Again Wednesday
10:07pm, Wednesday, 10'th Jun 2020
Nasdaq reports another new high Continue reading...
Why Biomarin's Stock Is Trading Higher Today
03:03pm, Wednesday, 10'th Jun 2020
BioMarin Pharmaceutical (NASDAQ: BMRN) shares are trading higher on Wednesday, after Bank of Americamaintained its Buy rating on the stock and raised the price target from $120 to $130 per share.BioMa
B of A Securities Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $130
11:52am, Wednesday, 10'th Jun 2020Why Biomarin's Stock Is Trading Higher Today
11:03am, Wednesday, 10'th Jun 2020
BioMarin Pharmaceutical (NASDAQ: BMRN) shares are trading higher on Wednesday, after Bank of Americamaintained its Buy rating on the stock and raised the price target from $120 to $130 per share.
Jefferies 5 High-Conviction Health Care Stocks to Buy for the Second Half
07:17am, Wednesday, 10'th Jun 2020
With the first half of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the second half of the year, with what should be
Hemophilia Treatment Market 2020 Industry Research, Share, Trend, Global Industry Size, Future Analysis, Regional Outlook to 2025
12:52pm, Tuesday, 09'th Jun 2020
Jun 09, 2020 (Market Insight Reports) --
Latest research report on 'Hemophilia Treatment Market' delivers a comprehensive study on current market trends. The...
The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid
12:00am, Friday, 05'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 4)
Biohaven Pharmaceutical...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs June 3)
Arena Pharmaceuticals, Inc. (...
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
12:30pm, Wednesday, 03'rd Jun 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D., President, Worldwide Research & Development; and Brian
BioMarin's Positive Hemophilia Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:BMRN)
01:09pm, Tuesday, 02'nd Jun 2020
BioMarin reported positive data for valoctocogene roxaparvovec in adults suffering from severe hemophilia A. Evolent loses Medicaid contract. Moderna begins dos
Avidity Biosciences Starts U.S. IPO Plan (Pending:RNA)
07:20pm, Monday, 01'st Jun 2020
Avidity Biosciences has filed to raise $100 million in an IPO, although the final figure may differ. The firm is development treatments for various muscular dys
Locked up in lockdown: The London criminals jailed in May
06:53pm, Monday, 01'st Jun 2020
Their crimes include rape, firearm possession, death by dangerous driving, Class A drugs possession and burglary
Xconomy: Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact
05:36pm, Monday, 01'st Jun 2020
Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases,
